Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherAssets,cash,totalCurrentLiabilities,propertyPlantEquipment,totalCurrentAssets,netReceivables,accountsPayable,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,changeToNetincome,capitalExpenditures,repurchaseOfStock,WC,language,region,quoteType,triggerable,quoteSourceName,currency,shortName,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,marketState,exchangeDataDelayedBy,priceHint,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,exchange,market,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,epsCurrentYear,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Aug 12, 2021) 4","Short Ratio (Aug 12, 2021) 4","Short % of Float (Aug 12, 2021) 4","Short % of Shares Outstanding (Aug 12, 2021) 4","Shares Short (prior month Jul 14, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,industry
t0,ETTX,53060000,37310300,9986000,,-12030000,,-12030000,3311000,0,-13297000,-13297000,,,,,,0,0,13297000,0,1267000,,-12030000,-12030000,260198000,10505000,53060000,88000,63565000,48000,888000,-207186000,63000,56406000,10144000,1080000,62422000,2657000,1045000,611000.0,-22000.0,19974000.0,2027000.0,19974000.0,11469000.0,-8483000.0,27000.0,882000.0,-22000.0,,52278000,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,Entasis Therapeutics Holdings I,0.16042188,105588144,-1.951724,1.9831814,15,America/New_York,EDT,-14400000,False,False,REGULAR,0,4,2.83,1630510036,0.03999996,2.77,2.84,2.77,42676,NGM,us_market,1.4336904,2.77 - 2.84,2.79,2.81,2.84,10,13,finmb_558232165,NasdaqGM,Entasis Therapeutics Holdings Inc.,USD,286085,139316,1.2499999,0.7911391,1.58 - 3.74,-0.9100001,-0.24331553,1.58,3.74,1616486400,1635937140,1636372800,-2.099,-1.45,-1.18,-2.3983052,1.427,2.47,0.3599999,0.14574894,2.4387681,0.39123178,1.88,,,3.74,1.58,2.47,2.4388,286.08k,139.32k,37.31M,,16.33M,65.75%,11.03%,438.95k,3.61,1.62%,0.93%,510.4k,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",0.00%,0.00%,-53.45%,-87.09%,,,,,-51.2M,-44.56M,-2.0990,,56.41M,1.19,1.02M,1.92,6.15,1.43,-39.44M,-26.98M,Value,02451,Healthcare,47,"Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant gram-negative bacteria in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections. The company has a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. for the development of durlobactam and SUL-DUR; and collaboration agreement with Global Antibiotic Research and Development Partnership for the development and commercialization of a product candidate containing zoliflodacin. Entasis Therapeutics Holdings Inc. was founded in 2015 and is headquartered in Waltham, Massachusetts.",Waltham,781 810 0120,MA,1609372800,United States,http://www.entasistx.com,86400,35 Gatehouse Drive,Biotechnology
t-1,ETTX,44257000,37310300,9370000,,-10701000,,-10701000,3307000,0,-12677000,-12677000,,,,,,0,0,12677000,0,1976000,,-10701000,-10701000,239375000,8568000,44257000,140000,52825000,38000,1338000,-195156000,63000,44937000,8033000,1217000,51545000,2559000,434000,-226000.0,-11000.0,1800000.0,-69000.0,1800000.0,-8310000.0,-10099000.0,28000.0,869000.0,-11000.0,,43512000,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,Entasis Therapeutics Holdings I,0.16042188,105588144,-1.951724,1.9831814,15,America/New_York,EDT,-14400000,False,False,REGULAR,0,4,2.83,1630510036,0.03999996,2.77,2.84,2.77,42676,NGM,us_market,1.4336904,2.77 - 2.84,2.79,2.81,2.84,10,13,finmb_558232165,NasdaqGM,Entasis Therapeutics Holdings Inc.,USD,286085,139316,1.2499999,0.7911391,1.58 - 3.74,-0.9100001,-0.24331553,1.58,3.74,1616486400,1635937140,1636372800,-2.099,-1.45,-1.18,-2.3983052,1.427,2.47,0.3599999,0.14574894,2.4387681,0.39123178,1.88,,,3.74,1.58,2.47,2.4388,286.08k,139.32k,37.31M,,16.33M,65.75%,11.03%,438.95k,3.61,1.62%,0.93%,510.4k,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",0.00%,0.00%,-53.45%,-87.09%,,,,,-51.2M,-44.56M,-2.0990,,56.41M,1.19,1.02M,1.92,6.15,1.43,-39.44M,-26.98M,Value,02451,Healthcare,47,"Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant gram-negative bacteria in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections. The company has a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. for the development of durlobactam and SUL-DUR; and collaboration agreement with Global Antibiotic Research and Development Partnership for the development and commercialization of a product candidate containing zoliflodacin. Entasis Therapeutics Holdings Inc. was founded in 2015 and is headquartered in Waltham, Massachusetts.",Waltham,781 810 0120,MA,1609372800,United States,http://www.entasistx.com,86400,35 Gatehouse Drive,Biotechnology
t-2,ETTX,52289000,37310300,9773000,,-10701000,,-10701000,2974000,0,-12747000,-12747000,,,,,,0,0,12747000,0,2046000,,-10701000,-10701000,236707000,9269000,52289000,106000,61558000,37000,835000,-184455000,63000,53247000,8565000,1363000,60132000,1890000,660000,54000.0,-18000.0,-210000.0,2147000.0,1800000.0,-7943000.0,-7715000.0,32000.0,753000.0,-18000.0,-210000.0,51567000,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,Entasis Therapeutics Holdings I,0.16042188,105588144,-1.951724,1.9831814,15,America/New_York,EDT,-14400000,False,False,REGULAR,0,4,2.83,1630510036,0.03999996,2.77,2.84,2.77,42676,NGM,us_market,1.4336904,2.77 - 2.84,2.79,2.81,2.84,10,13,finmb_558232165,NasdaqGM,Entasis Therapeutics Holdings Inc.,USD,286085,139316,1.2499999,0.7911391,1.58 - 3.74,-0.9100001,-0.24331553,1.58,3.74,1616486400,1635937140,1636372800,-2.099,-1.45,-1.18,-2.3983052,1.427,2.47,0.3599999,0.14574894,2.4387681,0.39123178,1.88,,,3.74,1.58,2.47,2.4388,286.08k,139.32k,37.31M,,16.33M,65.75%,11.03%,438.95k,3.61,1.62%,0.93%,510.4k,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",0.00%,0.00%,-53.45%,-87.09%,,,,,-51.2M,-44.56M,-2.0990,,56.41M,1.19,1.02M,1.92,6.15,1.43,-39.44M,-26.98M,Value,02451,Healthcare,47,"Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant gram-negative bacteria in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections. The company has a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. for the development of durlobactam and SUL-DUR; and collaboration agreement with Global Antibiotic Research and Development Partnership for the development and commercialization of a product candidate containing zoliflodacin. Entasis Therapeutics Holdings Inc. was founded in 2015 and is headquartered in Waltham, Massachusetts.",Waltham,781 810 0120,MA,1609372800,United States,http://www.entasistx.com,86400,35 Gatehouse Drive,Biotechnology
t-3,ETTX,62236000,37310300,9387000,,-11133000,,-11133000,3213000,0,-12600000,-12600000,,,,,,0,0,12600000,0,1467000,,-11133000,-11133000,235955000,7726000,62236000,179000,69962000,35000,2130000,-173754000,63000,61190000,6862000,1501000,68398000,1511000,815000,-928000.0,-18000.0,23566000.0,-1783000.0,23566000.0,10419000.0,-13147000.0,33000.0,664000.0,-18000.0,-210000.0,61536000,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,Entasis Therapeutics Holdings I,0.16042188,105588144,-1.951724,1.9831814,15,America/New_York,EDT,-14400000,False,False,REGULAR,0,4,2.83,1630510036,0.03999996,2.77,2.84,2.77,42676,NGM,us_market,1.4336904,2.77 - 2.84,2.79,2.81,2.84,10,13,finmb_558232165,NasdaqGM,Entasis Therapeutics Holdings Inc.,USD,286085,139316,1.2499999,0.7911391,1.58 - 3.74,-0.9100001,-0.24331553,1.58,3.74,1616486400,1635937140,1636372800,-2.099,-1.45,-1.18,-2.3983052,1.427,2.47,0.3599999,0.14574894,2.4387681,0.39123178,1.88,,,3.74,1.58,2.47,2.4388,286.08k,139.32k,37.31M,,16.33M,65.75%,11.03%,438.95k,3.61,1.62%,0.93%,510.4k,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",0.00%,0.00%,-53.45%,-87.09%,,,,,-51.2M,-44.56M,-2.0990,,56.41M,1.19,1.02M,1.92,6.15,1.43,-39.44M,-26.98M,Value,02451,Healthcare,47,"Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant gram-negative bacteria in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections. The company has a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. for the development of durlobactam and SUL-DUR; and collaboration agreement with Global Antibiotic Research and Development Partnership for the development and commercialization of a product candidate containing zoliflodacin. Entasis Therapeutics Holdings Inc. was founded in 2015 and is headquartered in Waltham, Massachusetts.",Waltham,781 810 0120,MA,1609372800,United States,http://www.entasistx.com,86400,35 Gatehouse Drive,Biotechnology
